within Pharmacolibrary.Drugs.ATC.J;

model J05AB17
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.73,
    Cl             = 3.733333333333334e-05,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0246,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.003,
    Tlag           = 15.0,            
    Vdp             = 0.0121,
    k12             = 2.11,
    k21             = 2.11
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AB17</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Brincidofovir is an oral lipid conjugate prodrug of cidofovir, an antiviral medication. It has activity against double-stranded DNA viruses and has been studied for treatment of serious viral infections such as smallpox and cytomegalovirus (CMV) in immunocompromised patients. The drug was granted emergency approval for smallpox under specific circumstances but is not generally approved for widespread clinical use globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Huston, J, et al., &amp; Egelund, EF (2023). Brincidofovir: A Novel Agent for the Treatment of Smallpox. <i>The Annals of pharmacotherapy</i> 57(10) 1198–1206. DOI:<a href=\"https://doi.org/10.1177/10600280231151751\">10.1177/10600280231151751</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36688308/\">https://pubmed.ncbi.nlm.nih.gov/36688308</a></p></li><li><p>Alvarez-Cardona, JJ, et al., &amp; Chemaly, RF (2020). Brincidofovir: understanding its unique profile and potential role against adenovirus and other viral infections. <i>Future microbiology</i> 15 389–400. DOI:<a href=\"https://doi.org/10.2217/fmb-2019-0288\">10.2217/fmb-2019-0288</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32166967/\">https://pubmed.ncbi.nlm.nih.gov/32166967</a></p></li><li><p>Hutson, CL, et al., &amp; Olson, VA (2021). Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model. <i>mSphere</i> 6(1) –. DOI:<a href=\"https://doi.org/10.1128/mSphere.00927-20\">10.1128/mSphere.00927-20</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33536322/\">https://pubmed.ncbi.nlm.nih.gov/33536322</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AB17;
